<DOC>
	<DOCNO>NCT03056703</DOCNO>
	<brief_summary>The primary objective study compare bioavailability single dose new 1000 mg fast release ASA ( acetylsalicylic acid ) tablet two tablet commercially available 500 mg fast release tablet test bioequivalence new versus commercial product healthy adult subject .</brief_summary>
	<brief_title>Bioequivalence Single Dose Fast Release Aspirin ( 1000 mg ) Tablet Versus Single Dose Two 500 mg Fast Release Aspirin Tablets</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy ambulatory male female subject 18 55 year age , inclusive Body Mass Index ( BMI ) approximately 18.5 30.0 kg/m2 , total body weight &gt; 50 kg ( 110 lb ) Results screen clinical laboratory test within normal limit consider clinically significant Principal Investigator Sponsor Female subject childbearing potential must use medically acceptable form birth control least 1 month prior screen ( 3 month oral contraceptive ) , e.g. , oral patch contraceptive , intrauterine device , intramuscular injection doublebarrier negative pregnancy test Screening Day 0 treatment period . Female subject nonchildbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy . Provide personally sign date informed consent prior inclusion trial indicate subject inform pertinent aspects trial . History hypersensitivity acetylsalicylic acid ( ASA ) , naproxen sodium , acetaminophen , nonsteroidal antiinflammatory drug ( NSAIDs ) , similar pharmacological agent component product History gastrointestinal bleeding perforation , include bleed related previous NSAID therapy . Active , history recurrent peptic ulcer/hemorrhage ( two distinct episode proven ulceration bleeding ) . Have take ASA , ASAcontaining product , acetaminophen NSAID ( OTC prescription ) seven day prior dose Treatment Periods , study product Loss blood excess 500 mL within 56 day first dose trial treatment ( e.g. , donation , plasmapheresis , injury ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease , malignancy Positive alcohol drug screen Screening Day 0 Treatment Periods 1 2 Females pregnant lactate Consumption xanthinecontaining food beverage within 24 h investigational medicinal product ( IMP ) administration Treatment Periods 1 2 ; willing abstain xanthine contain food beverage study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>